Close menu




May 16th, 2024 | 08:00 CEST

Share price shock at Siemens Energy! What are BioNTech and Cardiol Therapeutics doing?

  • Biotechnology
  • Pharma
  • renewableenergies
Photo credits: pixabay.com

The Siemens Energy share has been one of the surprises of recent months. It has more than doubled since the beginning of the year. Is a crash now imminent? Yes, if you believe Bernstein. Their analysts are shocking us with a horror price target. The Cardiol Therapeutics share performed even better than Siemens Energy in 2024. Despite the 150% rally, analysts see upside potential for the cardiovascular disease specialist. Things will get really exciting at the beginning of June when new study results are due. BioNTech, on the other hand, is currently failing to convince analysts. Reactions to the latest quarterly figures were modest.

time to read: 3 minutes | Author: Fabian Lorenz
ISIN: SIEMENS ENERGY AG NA O.N. | DE000ENER6Y0 , BIONTECH SE SPON. ADRS 1 | US09075V1026 , CARDIOL THERAPEUTICS | CA14161Y2006

Table of contents:


    Sébastien Plouffe, CEO, Founder and Director, Defence Therapeutics Inc.
    "[...] Defence will continue to develop its Antibody Drug Conjugates "ADC" and its radiopharmaceuticals programs, which are currently two of the hottest products in demand in the pharma industries where significant consolidations and take-overs occurred. [...]" Sébastien Plouffe, CEO, Founder and Director, Defence Therapeutics Inc.

    Full interview

     

    Cardiol Therapeutics: Next top news in June?

    The Cardiol Therapeutics share price has more than doubled this year, making it one of the top performers in the biotech sector in 2024. It is currently trading at USD 2.18, and analysts see even more potential. The experts at Canaccord recommend buying the shares of the specialist in cardiovascular diseases with a price target of USD 6. New study data, due to be published at the beginning of June, could trigger the next share price jump. The Company confirmed the schedule again on Tuesday.

    Cardiol reported that the Phase II study to assess the effects of CardiolRx™ on myocardial regeneration in patients with acute myocarditis ("ARCHER") was the subject of a presentation at the World Congress on Acute Heart Failure 2024 in Lisbon. Carsten Tschöpe from the Berlin Institute of Health Research at Charité presented the baseline data of the first 50 patients randomized in the ARCHER study. From Cardiol's perspective, the cardiology community is very interested in the novel approaches for the treatment of acute myocarditis, for which there are currently no therapies approved by the regulatory authorities in Europe and the US. The Company also stated that patient recruitment is progressing rapidly.

    Cardiol CEO David Elsley stated: "We are pleased to report that the ARCHER study has now reached over 85% of its target enrollment. We anticipate that the results of the ARCHER study will contribute to a better understanding of the therapeutic potential of CardiolRx™ and complement our already advanced Phase II MAvERIC-Pilot study in patients with recurrent pericarditis." Cardiol has again announced top-line results for the Phase II MAvERIC-Pilot study for early June 2024.

    The fact that Cardiol's share price is not showing any weakness ahead of the important data is a positive signal.

    BioNTech: How analysts are reacting to the quarterly figures

    BioNTech shareholders have been waiting for a positive signal for some time. The stock is trading at USD 92, well below its all-time high of USD 390 from 2021. The recently published quarterly figures have also failed to give the share price any new impetus. Analysts are also cautious. Since last week, there have only been "Hold" recommendations.

    BioNTech did not meet Goldman Sachs' expectations with its latest quarterly figures. According to the analysts, sales and profits were lower than expected. They, therefore, reduced the price target to USD 90. UBS is currently the most optimistic, although the analysts' fair value of USD 101 also offers only manageable upside potential. The experts consider BioNTech's oncology pipeline to be attractive. However, research takes time, and the share price will only likely benefit from this in the longer term. Deutsche Bank's price target for BioNTech shares is USD 95, and Jefferies believes the share price could reach USD 100.

    Siemens Energy: Share price soon -50%?

    Bernstein Research caused a stir on Tuesday with a possible halving of the Siemens Energy share price. The analysts pointed to risks in the US. An election victory for Donald Trump could lead to noticeable cuts in the German company's US business in the medium term. The Republican presidential candidate recently announced at a fundraising event that he would strengthen the domestic oil industry if he won the election. According to this, the promotion of renewable energies is to be massively curtailed. This is also likely to apply to offshore wind energy. Siemens Gamesa is a major player in this segment. Bernstein Research, therefore, rates the Siemens Energy share as "Underperform". The target price is EUR 12. However, the bulls are not letting this unsettle them at the moment. Yesterday alone, the share gained more than 1% and reached a new high for the year of EUR 24.51.

    Incidentally, Goldman Sachs is Siemens Energy's biggest fan among analysts. After last week's quarterly figures, it raised its price target from EUR 27 to EUR 32.70 and confirmed its "Buy" recommendation. The majority of analysts are also positive.

    Siemens Energy will report on its performance in the third quarter in August.


    Siemens Energy seems to have recovered from the past year's problems. Currently, a reference to the potential negative effects of a Donald Trump election victory is not enough to interrupt the stock's momentum. The Cardiol Therapeutics share continues to demonstrate strength, and analysts see plenty of room for growth. A short-term price jump is not expected for BioNTech, even though the long-term prospects appear positive.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Stefan Feulner on December 10th, 2024 | 07:30 CET

    Novo Nordisk, BioNxt Solutions, Bayer – The market continues to boom

    • Biotechnology
    • Biotech
    • Pharma

    The weight-loss drug market was one of the fastest-growing sectors in the past year and shows no signs of slowing down in 2025. Companies like Novo Nordisk have seen their valuations multiply in recent years, significantly boosting their market capitalization. At the same time, smaller life sciences companies in the second tier, such as those with breakthrough technologies, offer interesting entry opportunities.

    Read

    Commented by André Will-Laudien on December 10th, 2024 | 07:00 CET

    Biotech Acquisitions in 2025: Several 100% Gains Expected – Evotec, Vidac Pharma, BioNTech, and Pfizer

    • Biotech
    • Pharma
    • Biotechnology

    There have already been two attempts, but the story continues! Evotec speculators were confronted with a rumor mill and a takeover bid in November. This is what happens when a stock plummets and languishes for a long time. The management wisely rejected Halozyme's undervalued offer, and thus, the bidding war for the Hamburg-based company began anew. In the biotech sector, eyes should now be on the future, as the first movements have already taken place. In our stock selection, there are three outliers with price increases of more than 30% in the last 3 months. However, the big moves will only take place in 2025. Here is an analytical look at a long-neglected sector.

    Read

    Commented by André Will-Laudien on December 9th, 2024 | 07:15 CET

    DAX 20,400 – Year-end rally underway! 100% opportunities are still lurking at Shell, BP, Saturn Oil + Gas, Nel ASA, and Plug Power

    • Mining
    • Oil
    • renewableenergies
    • Hydrogen
    • Fuelcells

    All EU countries have ramped up their alternative energy production in recent years. In particular, countries like Germany achieved a 65% share of electricity from renewable sources in the first half of 2024, with wind and solar as the main drivers of growth. However, the conflict in Ukraine since 2022 has now jeopardized the achievement of the 2050 targets more than ever because the lack of affordable fossil gas is threatening the transformation of the economy. The rising gas prices of recent weeks have awakened bad memories of 2022 among European energy traders and politicians alike. When the continent was in a rush to end its dependence on Russian gas, prices had already risen by 400%. The energy sector offers great opportunities – timing is of the essence!

    Read